

OCT. 5. 2005 3:36PM

RECEIVED
CENTRAL FAX CENTER

OCT 05 2005

NO. 6068 P. 11

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Shah, et al.

Serial No.: 09/891,983

Filed: June 26, 2001

For: METHODS FOR THE
SIMULTANEOUS DETECTION OF HCV
ANTIGENS AND HCV ANTIBODIES

Case No.: 6821.US.01

Examiner: Z. Lucas

Group Art Unit: 1648

Certificate of Facsimile Transmission under 37
CFR §1.8(a):

I hereby certify that this paper (along with any
paper referred to as being attached or enclosed) is
being transmitted via facsimile, said transmission to
be completed before midnight Eastern time on the
date shown below, addressed to the following
recipient:

Examiner Zachariah Lucas

Group Art Unit 1648

Commissioner of Patents

Recipient Facsimile No.: (571) 273-8300

Kimberly Lorio 10/5/05
Kimberly Lorio Date

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The following information is submitted pursuant to 37 C.F.R. §1.97 and §1.98 in accordance with Applicants' duty of disclosure under 37 C.F.R. §1.56. This submission is not an admission that the documents cited herein are prior art as to the invention claimed. In accordance with 37 CFR §§1.97(g)-(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that other material information as defined by 37 CFR §1.56(a) exists.

Applicants submit herewith Form PTO-1449 listing the references known to them. Applicants respectfully request that the Examiner (1) initial each reference listed on the enclosed Form PTO-1449 indicating that the Examiner has considered and made those references of record in this application and (2) return a copy of the initialed Form PTO 1449 to Applicants. Copies of the references are also enclosed.

Documents listed in this Supplemental Information Disclosure Statement were first cited in an Preliminary Examination Report, dated October 4, 2004, issued in connection with counterpart PCT application No. PCT/US02/19958.

This Supplemental Information Disclosure Statement is submitted after the first Office Action on the merits, but before the issuance of a final action or a notice of allowance. Authorization to charge Deposit Account No. 01-0025 in the amount necessary to cover the cost of this Supplemental Information Disclosure Statement under 37 C.F.R. 1.17(p) is provided in the Transmittal Letter, submitted herewith.

Respectfully submitted,
Shah, et al.

ABBOTT LABORATORIES
Customer No.: 23492
Telephone: (847) 935-1729
Facsimile: (847) 938-2623

Cheryl L. Becker
Cheryl L. Becker
Registration No. 35,441
Attorney for Applicants

